H
Hemu (China) Biological Engineering
Interventional medical devices for neurovascular and peripheral diseases
About Hemu (China) Biological Engineering
Hemu (China) Biological Engineering Co., Ltd. is a medical device company established in 2016, with formal operations beginning in 2017. The company was founded by Dr. Jack Wang (Wang Jicheng), an industry veteran with extensive experience in the medical device sector, including roles at Abbott and Johnson & Johnson, and as CEO of Biosensors International Group. His first entrepreneurial success was founding JW Medical Systems, which became one of China's top three developers of coronary drug-eluting stents, breaking foreign monopoly in the field.
The company focuses on designing, developing, and manufacturing innovative interventional medical devices for vascular diseases, particularly for the treatment of stroke. It provides comprehensive solutions for ischemic stroke, hemorrhagic stroke, and intracranial vascular stenosis. The firm operates on a global scale, with a Singapore headquarters, R&D centers in both Singapore and China, collaborations with labs in the U.S., and a production base in Weihai, Shandong province.
Hemu's product portfolio includes a range of devices for neurovascular and peripheral interventions. A key achievement was the 2021 launch of its Afentta™ intracranial thrombus aspiration catheter, the first such domestic device to receive approval from China's National Medical Products Administration (NMPA), addressing a significant market gap. Other commercialized products include the TracLine™ access catheter and the FocuStar neuro balloon catheter. The company has a deep pipeline with over a dozen products in preclinical stages and several others in clinical trials or under registration review. One of its peripheral non-vascular products is the Privi™ cooling balloon, a device for treating hemorrhoids through physical mechanisms.
Hemu generates revenue through the sale of its medical devices. The company has attracted significant investment from notable firms, including Hudson Bay Capital Management, OrbiMed, Lilly Asia Ventures, and Hillhouse Capital (Gao Ling Venture Capital), completing a Series C funding round of $50 million in late 2020.
Source: Dealroom company dataNews
Open roles
Hemu (China) Biological Engineering in the Weihai ecosystem
The Hemu (China) Biological Engineering office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Hillhouse Capital
3H Health Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hemu (China) Biological Engineering on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hemu (China) Biological Engineering on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.